Analyst Price Targets — TNDM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 12:28 pm | Kendall Au | RBC Capital | $26.00 | $20.18 | TheFly | Tandem Diabetes price target lowered to $26 from $30 at RBC Capital |
| August 7, 2026 11:39 am | William Plovanic | Canaccord Genuity | $40.00 | $18.79 | TheFly | Tandem Diabetes price target raised to $40 from $35 at Canaccord |
| July 28, 2026 11:57 am | — | UBS | $18.00 | $17.86 | TheFly | Tandem Diabetes resumed with a Neutral at UBS |
| June 23, 2026 11:41 am | — | Deutsche Bank | $15.50 | $14.34 | TheFly | Tandem Diabetes initiated with a Hold at Deutsche Bank |
| June 1, 2026 1:11 am | — | Wells Fargo | $27.00 | $17.20 | TheFly | Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo |
| May 27, 2026 11:27 am | — | Goldman Sachs | $21.00 | $14.54 | TheFly | Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs |
| May 11, 2026 9:49 am | — | Barclays | $55.00 | $15.48 | TheFly | Tandem Diabetes price target lowered to $55 from $56 at Barclays |
| May 8, 2026 11:20 am | Anthony Petrone | Mizuho Securities | $24.00 | $18.47 | TheFly | Tandem Diabetes price target raised to $24 from $22 at Mizuho |
| April 24, 2026 8:58 am | Issie Kirby | Redburn Partners | $45.00 | $20.68 | TheFly | Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn |
| February 23, 2026 12:44 pm | — | Truist Financial | $27.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $27 from $24 at Truist |
Latest News for TNDM
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
On September 10, 2026, Tandem Diabetes Care Inc (TNDM) shares fell 4.2% to a current price of $18.31. The stock has experienced notable volatility, trading betw
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TNDM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.